Abstract
Objective: The aim of this study was to compare the effects on urinary albumin excretion (UAE) of amlodipine versus fosinopril in elderly hypertensive patients with type 2 diabetes mellitus. Methods: We studied 147 elderly (60 to 75 years) hypertensive patients (diastolic blood pressure > 90 mm Hg) with concomitant, well-controlled type 2 diabetes mellitus. After a 4- week placebo period (at the beginning of which current antihypertensive agents were discontinued), they were randomly allocated to receive amlodipine 5 to 10 mg once daily (n = 73) or fosinopril 10 to 20 mg once dally (n = 74) for 24 months. Nonresponders to monotherapy were discontinued after 8 weeks. At the end of the placebo period and after 3, 6, 12, 18, and 24 months of treatment, blood pressure (BP), glycosylated hemoglobin A(1c), UAE, and creatinine clearance were determined. Results: Seventy-nine patients completed the 24-month study. Both amlodipine and fosinoprll similarly reduced BP without affecting glucose homeostasis. At 3 months, UAE was significantly reduced (P <0.01) only in the fosinopril-treated patients; however, at 12 and 24 months, it was significantly decreased with both drugs (fosinopril, P <0.01; amlodipine, P <0.05). Creatinine clearance was unaffected by fosinopril but was significantly increased (P <0.05) by amlodipine at 12 months. Conclusions: Based on these results, we concluded that long-term treatment with both amlodipine and fosinopril was effective in reducing UAE in elderly hypertensive patients with type 2 diabetes mellitus and microalbuminuria.
| Original language | English |
|---|---|
| Pages (from-to) | 163-173 |
| Number of pages | 11 |
| Journal | Current Therapeutic Research |
| Volume | 61 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Amlodipine
- Elderly
- Fosinopril
- Type 2 diabetes mellitus
- Urinary albumin excretion
ASJC Scopus subject areas
- Medicine(all)
Cite this
Long-term effects of amlodipine versus fosinopril on microalbuminuria in elderly hypertensive patients with type 2 diabetes mellitus. / Fogari, Roberto; Zoppi, Annalisa; Corradi, Luca; Poletti, Luigi; Pasotti, Michele; Fogari, Elena; Mugellini, Amedeo.
In: Current Therapeutic Research, Vol. 61, No. 3, 2000, p. 163-173.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term effects of amlodipine versus fosinopril on microalbuminuria in elderly hypertensive patients with type 2 diabetes mellitus
AU - Fogari, Roberto
AU - Zoppi, Annalisa
AU - Corradi, Luca
AU - Poletti, Luigi
AU - Pasotti, Michele
AU - Fogari, Elena
AU - Mugellini, Amedeo
PY - 2000
Y1 - 2000
N2 - Objective: The aim of this study was to compare the effects on urinary albumin excretion (UAE) of amlodipine versus fosinopril in elderly hypertensive patients with type 2 diabetes mellitus. Methods: We studied 147 elderly (60 to 75 years) hypertensive patients (diastolic blood pressure > 90 mm Hg) with concomitant, well-controlled type 2 diabetes mellitus. After a 4- week placebo period (at the beginning of which current antihypertensive agents were discontinued), they were randomly allocated to receive amlodipine 5 to 10 mg once daily (n = 73) or fosinopril 10 to 20 mg once dally (n = 74) for 24 months. Nonresponders to monotherapy were discontinued after 8 weeks. At the end of the placebo period and after 3, 6, 12, 18, and 24 months of treatment, blood pressure (BP), glycosylated hemoglobin A(1c), UAE, and creatinine clearance were determined. Results: Seventy-nine patients completed the 24-month study. Both amlodipine and fosinoprll similarly reduced BP without affecting glucose homeostasis. At 3 months, UAE was significantly reduced (P <0.01) only in the fosinopril-treated patients; however, at 12 and 24 months, it was significantly decreased with both drugs (fosinopril, P <0.01; amlodipine, P <0.05). Creatinine clearance was unaffected by fosinopril but was significantly increased (P <0.05) by amlodipine at 12 months. Conclusions: Based on these results, we concluded that long-term treatment with both amlodipine and fosinopril was effective in reducing UAE in elderly hypertensive patients with type 2 diabetes mellitus and microalbuminuria.
AB - Objective: The aim of this study was to compare the effects on urinary albumin excretion (UAE) of amlodipine versus fosinopril in elderly hypertensive patients with type 2 diabetes mellitus. Methods: We studied 147 elderly (60 to 75 years) hypertensive patients (diastolic blood pressure > 90 mm Hg) with concomitant, well-controlled type 2 diabetes mellitus. After a 4- week placebo period (at the beginning of which current antihypertensive agents were discontinued), they were randomly allocated to receive amlodipine 5 to 10 mg once daily (n = 73) or fosinopril 10 to 20 mg once dally (n = 74) for 24 months. Nonresponders to monotherapy were discontinued after 8 weeks. At the end of the placebo period and after 3, 6, 12, 18, and 24 months of treatment, blood pressure (BP), glycosylated hemoglobin A(1c), UAE, and creatinine clearance were determined. Results: Seventy-nine patients completed the 24-month study. Both amlodipine and fosinoprll similarly reduced BP without affecting glucose homeostasis. At 3 months, UAE was significantly reduced (P <0.01) only in the fosinopril-treated patients; however, at 12 and 24 months, it was significantly decreased with both drugs (fosinopril, P <0.01; amlodipine, P <0.05). Creatinine clearance was unaffected by fosinopril but was significantly increased (P <0.05) by amlodipine at 12 months. Conclusions: Based on these results, we concluded that long-term treatment with both amlodipine and fosinopril was effective in reducing UAE in elderly hypertensive patients with type 2 diabetes mellitus and microalbuminuria.
KW - Amlodipine
KW - Elderly
KW - Fosinopril
KW - Type 2 diabetes mellitus
KW - Urinary albumin excretion
UR - http://www.scopus.com/inward/record.url?scp=0034035669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034035669&partnerID=8YFLogxK
U2 - 10.1016/S0011-393X(00)80014-4
DO - 10.1016/S0011-393X(00)80014-4
M3 - Article
VL - 61
SP - 163
EP - 173
JO - Current Therapeutic Research - Clinical and Experimental
JF - Current Therapeutic Research - Clinical and Experimental
SN - 0011-393X
IS - 3
ER -